Alaunos Therapeutics, Inc. (TCRT)

Market Cap	17.93M
Revenue (ttm)	5,000
Net Income (ttm)	-35.14M
Shares Out	16.01M
EPS (ttm)	-2.20
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	49,703
Open	1.210
Previous Close	1.220
Day's Range	1.100 - 1.260
52-Week Range	0.600 - 10.500
Beta	-0.36
Analysts	Hold
Price Target	n/a
Earnings Date	May 8, 2024

About TCRT

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor engine. The company has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The Univers...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1998
• Employees: 1
• Stock Exchange: NASDAQ
• Ticker Symbol: TCRT

Financial Performance

In 2023, TCRT's revenue was $5,000, a decrease of -99.83% compared to the previous year's $2.92 million. Losses were -$35.14 million, -6.86% less than in 2022.